Hypothesis

Senescent endothelial and smooth‑muscle cells in the aging vasculature do not merely drive pathology; they also secrete a SASP‑enriched TGF‑β1/Peptide cocktail that keeps resident progenitor cells in a quiescent, reparative state. When senolytics abolish this signaling niche, progenitor cells proliferate unchecked, depositing excess collagen and elastin fragments that stiffen the artery wall. Thus, the net effect of senolysis depends on the balance between SASP‑mediated progenitor restraint and the intrinsic pro‑fibrotic drive of those progenitors. Supplementing TGF‑β1 (or mimicking its downstream Smad2/3 signaling) during senolytic treatment should preserve the protective restraint while clearing the damaging SASP components, preventing the fibrosis‑induced rise in arterial stiffness.

Mechanistic Rationale

1. SASP composition matters – While IL‑6, TNF‑α, and MMPs dominate the deleterious SASP, recent proteomics of senescent vascular cells show a concurrent rise in latent TGF‑β1 and its activators (e.g., thrombospondin‑1) [1 [2]. TGF‑β1 is a potent inhibitor of endothelial‑to‑mesenchymal transition (EndMT) and suppresses collagen‑I transcription in adventitial fibroblasts via Smad7 feedback.
2. Progenitor cell niche – The vasculature harbors Sca‑1⁺/CD34⁺ resident progenitors that contribute to neointimal formation after injury. In vitro, TGF‑β1 blocks their proliferation and shifts them toward a contractile phenotype (α‑SMA⁺) [3]. Senescent cells, by presenting TGF‑β1 on their surface or in exosomes, create a localized inhibitory gradient.
3. Senolytic perturbation – Dasatinib + quercetin (D+Q) efficiently clears p16^INK4a^‑positive vascular cells [4]. Removal of the TGF‑β1 source lifts the brake on progenitors, leading to hyper‑proliferation and excessive matrix deposition, which we predict will manifest as increased collagen cross‑linking and elevated pulse‑wave velocity (PWV).
4. Rescue by TGF‑β1 supplementation – Low‑dose recombinant TGF‑β1 or a Smad2/3 agonist (e.g., SIS3) administered concurrently with senolytics should re‑establish the progenitor‑restraining signal without reinstating the full proinflammatory SASP, thereby uncoupling senescent‑cell clearance from fibrosis.

Testable Predictions

• Prediction 1: In 24‑month‑old ApoE⁻/⁻ mice, D+Q treatment alone will reduce p16^INK4a^^+^ vascular cells by ~70% but increase medial collagen‑I area fraction by 35% and raise PWV by 20% relative to vehicle controls (measured at 4 weeks post‑treatment).
• Prediction 2: Co‑administration of D+Q with a TGF‑β1‑neutralizing antibody will exacerbate the collagen increase and PWV rise, confirming that endogenous TGF‑β1 from senescent cells is protective.
• Prediction 3: Co‑administration of D+Q with a low‑dose TGF‑β1 agonist (1 ng/g/day) will retain senescent‑cell clearance (>60% reduction) while preventing the collagen and PWV elevations observed with D+Q alone.
• Prediction 4: Single‑cell RNA‑seq of isolated vascular progenitors will show a shift from a quiescent (Cdkn1a^low^, Tagln^high^) to a proliferative (Mki67^high^, Col1a1^high^) signature after D+Q, which is blunted by TGF‑β1 agonist co‑treatment.

Falsifiability

If senolytic clearance of vascular senescent cells consistently reduces arterial stiffness irrespective of TGF‑β1 modulation (i.e., predictions 1‑3 fail), the hypothesis that senescent cells provide a progenitor‑restraining TGF‑β1 signal is falsified. Conversely, if TGF‑β1 supplementation abolishes the senolytic‑induced fibrosis benefit, the hypothesis gains support.

Experimental Outline

• Animals: 24‑month‑old male ApoE⁻/⁻ mice (n=10/group).
• Groups: (1) Vehicle, (2) D+Q, (3) D+Q + TGF‑β1 neutralizing Ab, (4) D+Q + low‑dose TGF‑β1 agonist, (5) TGF‑β1 agonist alone.
• Interventions: Intraperitoneal injections twice weekly for 3 weeks; TGF‑β1 agonist via osmotic pump.
• Readouts: (a) Senescent cell burden (p16^INK4a^ immunostaining), (b) Medial collagen‑I (picrosirius red under polarized light), (c) Elastin fragmentation (Verhoeff‑Van Gieson), (d) PWV (doppler ultrasound), (e) progenitor proliferation (Ki67^+^/Sca‑1^+^), (f) SASP cytokine profile (Luminex).
• Statistical analysis: One‑way ANOVA with Tukey post‑hoc; significance set at p<0.05.

Implications

If validated, this work reframes senolytics not as blunt instruments but as precision tools that must be paired with context‑specific niche support. It explains why some senolytic trials show mixed outcomes on cardiovascular endpoints and suggests a combinatorial strategy: clear the senescent cells while preserving or mimicking their homeostatic SASP components. Success would shift the field from indiscriminate senocyte ablation to senomorphic modulation, preserving the hostage‑negotiator function while disarming the harmful demands.